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Mantle Cell Lymphoma of Mucosa-Associated
Lymphoid Tissue: A European Mantle Cell
Lymphoma Network Study
Lucia Morello1, Sara Rattotti2, Laura Giordano3, Mats Jerkeman4, Tom van Meerten5, Katarzyna Krawczyk6,
Filipa Moita7, Dario Marino8, Simone Ferrero9, Michał Szymczyk10, Igor Aurer11, Tarec Christoffer El-Galaly12,
Alice Di Rocco13, Carlo Visco14, Giuseppe Carli15, Irene Defrancesco2, Carmelo Carlo-Stella1,16, Martin
Dreyling17, Armando Santoro1,16, Luca Arcaini2,18
Correspondence: Luca Arcaini (e-mail: luca.arcaini@unipv.it).
Abstract
While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated
extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the
European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with
isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78
patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%),
gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients
showed multiple extranodal sites. The median follow-up was 80 months (range: 6–182), 5-year progression-free survival (PFS) was
45% (95% CI: 35–54) and 5-year overall survival (OS) was 71% (95% CI: 62–79). In an explorative setting, we compared MALT MCL
with a group of 128 cMCL patients: MALTMCL patients showed a significantly longer PFS andOS compared with nodal cMCL; with a
median PFS of 4.5 years vs 2.8 years (p=0.001) and median OS of 9.8 years vs 6.9 years (p=0.018), respectively. Patients with
MALTMCL at diagnosis showed amore favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL
should be acknowledged to avoid possible over-treatment.
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Introduction
In addition to classical nodal mantle cell lymphoma (cMCL),
an aggressive disease requiring high-intensity chemotherapy,1,2
the 2016 update of the WHO classification of lymphoid
neoplasms recognizes the less common leukemic non-nodal
variant (nnMCL), characterized by lymphocytosis and spleno-
megaly without nodal disease, showing an indolent clinical
course.3–5
In particular, the leukemic nnMCL is represented by cells that
have experienced follicular germinal center and carry IgVH
somatic hypermutation with a discriminant gene-expression
profiling;7–8 this variant is frequently associated with a >7 years
survival.1 Correct identification of this variant has a potential
clinical impact, since this subset of MCL can benefit from a
watch-and-wait or a more conservative approach.6
Extranodal involvement in classical nodal MCL is common,
and gastrointestinal tract is the most involved site, often found
endoscopically in asymptomatic patients or as multiple lympho-
matoid polyposis.9,10 Infiltration of breast, lung, skin, soft tissue,
salivary gland and orbit are also seen. Involvement ofmore than 2
extranodal sites occurs in 30% to 50% of patients. However,
isolated extranodal disease (ED) is rarely detected in cMCL at
diagnosis and only a few reports are available: therefore, in
everyday clinical practice it is not possible to define the optimal
treatment strategy.11,12
On behalf of the European MCL Network, we conducted a
multicenter study, which collected MCL cases characterized by
isolated or predominant extranodal disease (which we defined
MALT MCL).
Patients and methods
Study design
This was a retrospective multicenter study conducted on behalf
of the European MCL Network. Consecutive MCL subjects
characterized by isolated or predominant ED were enrolled, from
1998 to 2015, by all participating centers. We captured baseline
clinical, laboratory and pathology data, initial therapy, and
active follow-up of all patients for relapse/progression and death
in order to describe a possible variant of MCL with a peculiar
clinical presentation in MALT sites.
Afterward, we compared MALT MCL with a group of
classical nodalMCL patients consecutively diagnosed in the same
period in 2 major Italian centers in order to describe, in an
explorative intention, the outcomes and the distribution of
prognostic factors between the 2 groups.
The study was approved by the Ethics Committee/institutional
Review Boards/data protection agencies of participating sites.
Patients providedwritten consent to participatewhen appropriate.
Selection criteria
All patients in the MALT MCL cohort were aged >18 years
and presented at diagnosis with only extranodal site (ES)
involvement or predominant extranodal disease with minimal
locoregional lymphadenopathy defined as CT scan longest axis
<2cm. nnMCL characterized by splenomegaly and lymphocy-
tosis without nodal involvement were excluded. Patients with
involvement of tonsils andWaldeyer ring sites were also included
in the extranodal group. Diagnosis of MCL was established
according to the WHO classification criteria and confirmed by
immunohistochemistry for cyclin D1 detection and/or FISH for
translocation (11;14).
Staging procedures were not standardized but varied depend-
ing on different centers, they included chest and abdomen
imaging investigations (computed tomography [CT]) and bone
marrow biopsy in all patients; ultrasound [US] scans, digestive
tract endoscopic investigations and ear, nose and throat (ENT)
evaluation in selected cases.
In the comparative cohort, we included patients with classical
nodal involvement with or without concomitant ED.
Statistical methods
Study endpoints included progression-free survival (PFS), early
and late progression of disease (POD) and overall survival (OS),
duration of response, time to next treatment andOS from relapse/
progression (OS-2) [as defined in Supplementary material,
Supplemental Digital Content, http://links.lww.com/HS/A46].
Data were summarized by descriptive statistics. Differences
between groups were evaluated by the Chi-square test or t test
(Fisher exact test andWilcoxon test, when appropriate). Survival
(OS and PFS) was estimated using the Kaplan-Meier method and
differences between groups were evaluated by the log-rank test
(or the trend test when appropriate).
Both in the univariable and multivariable analyses, the effect of
clinical or demographical factors on survival were evaluated
using the Cox proportional hazards model. In order to identify
variables impacting OS and PFS in MCL, the following
parameters were evaluated: gender, simplified prognostic index
for advanced stage MCL (sMIPI),13 Ki-67 index,14 cytology,15
Ann Arbor stage, bone marrow involvement, leukemic disease,
splenomegaly, type of treatment (ASCT) and clinical variant of
disease (MALT vs cMCL). ASCT was considered as a time-
dependent variable.
A p-value <0.05 was considered statistically significant (2
sides). All statistics were performed using SAS version 9.4.
Results
Patients characteristics and treatment of MALT
MCL
We collected data from 127 patients with MALT MCL in 14
European centers from 1998 to 2015.
Median age at diagnosis was 65 years (range: 36–85), patients
were predominantly male (61%) with a good performance status
(Eastern Cooperative Oncology Group 0 in 94 patients, 74%)
and localized disease (Ann Arbor stage I/II in 73 patients, 57%)
(Table 1). Twenty-seven patients showed a bone marrow
involvement in addition to ES, and 2 patients had also leukemic
disease. Histological and molecular features of MALT MCL
patients are summarized in Table S1 (Supplemental Digital
Content, http://links.lww.com/HS/A46).
Seventy-four patients (58%) with MALT MCL had minimal
locoregional lymphadenopathy at diagnosis. Involved ES
included: upper airways and Waldeyer ring (40 patients,
31%), gastrointestinal tract (32 patients, 25%), ocular adnexa
(17 patients, 13%) oral cavity and salivary glands (17 patients,
13%). Other less frequent sites were skin (n=3), thyroid (n=3),
breast (n=1), liver (n=1), testicle (n=1), bone (n=1), paranasal
sinus (n=1), kidney (n=1), larynx (n=1) and in 7 patients
multiple MALT sites were involved at diagnosis.
L. Morello et al. Extranodal MCL of MALT
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The majority of patients fell into the low and intermediate
sMIPI categories (84%).
Most patients (94%) treated with chemotherapy regimen
received concomitant rituximab; 41 patients received induction
therapy containing high-dose cytarabine followed by ASCT in 30
cases (24%). Other induction therapies included R-CHOP-like
(n=44) and R-bendamustine (n=6). Data on therapy were not
available for three patients. A minority received rituximab single
agent (n=4) or radiotherapy (n=27), and a watch-and-wait
policy was chosen in only 2 patients.
Twenty-five patients (25/27; 92%) treated with radiotherapy
alone had a limited stage of disease (stage 1). They experienced 5-
year PFS and OS of 53% and 70%, respectively.
Patients who underwent ASCT were mainly in advanced stage
(23/30; 77%) compared with those treated with more conserva-
tive regimens (31/97; 32%). Only 2 patients underwent allogenic
stem cell transplantation after a relapse to ASCT.
Outcome and prognosis of MALT MCL
Overall response rate to the primary treatment was 97%, and
median duration of response and time to next treatment
were 31.1 months (range: 1.3–169.4) and 22.4 months (range:
0.6–85.5), respectively.
We observed 44 deaths (median follow-up 80 months; 6–182),
of which 34% were due to disease progression. Other causes of
death included: other neoplasms (8 patients, 28%), treatment-
related toxicity (8 pts, 28%) and no known cause (13 patients,
45%).
Thirty-three patients relapsed, 82% of patients had isolated
extranodal involvement and only four patients (12%) had
systemic nodal disease. A total of 19% of patients (6/31) who
received rituximab single-agent or RT alone relapsed.
During follow-up, 16 patients developed secondary malignan-
cies (3 acute myeloid leukemia, 1 myelodysplastic syndrome and
12 solid neoplasia) corresponding to a cumulative incidence of
8.7% at 5 years. Median time from diagnosis to the second
neoplasm was 17.6 months (6–106).
PFS and OS at 5 years was 45% (95% CI: 35–54) and 71%
(95% CI: 62–79), respectively.
In the univariable analysis (Table 2), age >65 years, high
sMIPI, ECOG ≥1 and bone marrow involvement showed a
negative impact on PFS. In the multivariable model, only sMIPI
confirmed its statistically significant effect. Factors affectingOS in
univariable analysis (Table 2) were age >65 years, high sMIPI,
ECOG ≥1 and Ki-67 ≥30%. In the multivariable analysis, sMIPI
and Ki-67 confirmed their statistically significant impact on OS.
The effect of transplant on PFS (hazard ratio [HR]: 0.59, 95%CI:
0.29–1.19; p=0.139) and OS (HR: 0.58, 95% CI: 0.24–1.38;
p=0.215) was not significant even when adjusted for the other
factors.
In MALT MCL, we did not observe a different outcome
according to cytology (5-year PFS of 46% vs 44% for blastoid
and classic cytology, respectively) and type of ES.
Early POD occurred in 18/43 (42%) patients. OS-2 for patients
with early and late POD was 35.4% and 69.1% at 5 years,
respectively (p=0.002). Patients with late POD had an extremely
favorable prognosis (median OS-2 not reached).
Comparison with nodal MCL
MALT MCL patients were compared to 128 patients with
cMCL (Table 1). Median age was 65 years in both cohorts. We
observed a slightly higher female prevalence in the MALT MCL
cohort (39% vs 26%; p=0.029). The unfavorable features as
high sMIPI, Ki-67 ≥30% and blastoid/pleomorphic cytology
showed a homogenous distribution in the 2 groups. Patients with
MALTMCL had lower LDH values (p=0.002) at diagnosis and
a more often limited disease (stage I/II) than patients with cMCL
(57% vs 9%, respectively; p<0.001).
Regarding secondary ES in cMCL, 57 patients (44%)
presented with at least one extranodal involvement at diagnosis
Table 1
Features of 127 patients with MALT mantle cell lymphoma and 128
patients with classical nodal mantle cell lymphoma
MALT MCL Nodal cMCL
Feature N % N % p-value
Sex
Male 78 61 95 74 0.029
Female 49 39 33 26
Age
65 years 61 48 62 48 0.948
>65 years 66 52 66 52
sMIPI
Low 56 45 49 42 0.877
Intermediate 48 39 48 41
High 20 16 20 17
Missing 3 11
Ann Arbor stage
I/II 73 57 11 9 <0.001
III/IV 54 43 117 91
Bone marrow involvement
Negative 93 78 34 27 <0.001
Positive 27 22 90 73
Missing 7 4
Leukemic disease
No 125 98 97 76 <0.001
Yes 2 2 31 24
Ki-67 proliferation index
Low (<30%) 45 63 52 53 0.219
High (≥30%) 27 37 46 47
Missing 55 30
Cytology
Blastoid/pleomorhic 14 11 18 15 0.406
Classic 111 89 104 85
Missing 2 6
ECOG PS
0 94 74 103 81 0.176
≥1 33 26 24 19
Missing 1
B symptoms
No 84 68 105 83 0.006
Yes 39 32 21 17
Missing 4 2
ASCT
No 97 76 75 59 0.002
Yes 30 24 53 41
High-dose cytarabine
No 83 67 72 57 0.111
Yes 41 33 54 43
Missing 3 2
Minimal adenopathy
No 53 42
Yes 74 58
ASCT = autologous stem cell transplantation, ECOG = Eastern Cooperative Oncology Group,
MALT = mucosa-associated lymphoid tissue, MCL = mantle cell lymphoma, MIPI = Mantle Cell
Lymphoma International Prognostic Index, PS = performance status, cMCL = classical nodal MCL.
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in addition to bone marrow (gastrointestinal tract in 21 patients,
Waldeyer’s ring in 12 patients and multiple ES in 14 patients).
Regarding treatment, cMCL were treated with more
intensive regimens compared with the MALT type; 41% and
24% of patients underwent ASCT (p=0.002), respectively. No
patient in the nodal cMCL group was treated with radiotherapy
alone.
Median follow-up was 85.4 months (range: 6–218) and was
not different from that of MALT MCL. The incidence of
secondary malignancies was similar between the 2 groups.
MALT MCL patients showed a longer OS and PFS compared
with cMCL:medianOS 9.8 years vs 6.9 years (5-year OS: 71% vs
63%; HR: 0.63, 95% CI: 0.43–0.92; p=0.017) and median PFS
4.5 years vs 2.8 years, respectively (5-year PFS: 45% vs 28%;
HR: 0.54, 95% CI: 0.40–0.75; p<0.001) (Fig. 1). In addition,
when comparing only MALT patients with Waldeyer ring
involvement to cMCL we observed that PFS was longer for
MALT MCL than nodal type (p=0.01).
Univariable analysis for PFS and OS of the cMCL cohort is
summarized in Table S2 (Supplemental Digital Content, http://
links.lww.com/HS/A46).
When restricting the analysis to patients with unfavorable
cytology (blastoid/pleomorphic variant), PFS was significantly
longer in MALT MCL compared with cMCL (Fig. S1,
Supplemental Digital Content, http://links.lww.com/HS/A46).
To evaluate the prognostic impact of proposed novel clinical
variant of the disease, a model was constructed in the whole
population considering the clinical variant as a variable (MALT
vs cMCL). In the whole MCL population, in the univariable
analysis, factors affected PFS were age >65 years, stage III/IV,
bone marrow involvement, ECOG ≥1, Ki-67 ≥30%, blastoid/
pleomorphic cytology and no ASCT. In the univariable model for
OS, all investigating factors for PFS remained significant except
stage III/IV (Table S3, Supplemental Digital Content, http://links.
lww.com/HS/A46). Clinical disease variant resulted as an
independent prognostic factor for PFS (HR: 0.57; 95% CI:
0.37–0.86; p=0.007) adjusted for all factors which confirmed
their effect (Table 3).
The introduction of Ki-67 proliferation index into the
multivariable model reduced the number of observations (from
241 to 165) and events (from 151 to 105 for PFS and from 99 to
67 for OS) due to the large number of missing data. Since Ki-67
constitutes a known strong prognostic factor that cannot be
excluded from the analysis, we built the model comprising it
(Table 3).
Table 2
Univariable analysis for progression-free survival and overall
survival in 127 patients with MALT mantle cell lymphoma
PFS OS
Factor 5-year (%) p-value 5-year (%) p-value
All 44.8 71.1
Sex
Male 42.8 0.808 69.3 0.76
Female 47.3 73.4
Age
65 years 59.3 <0.001 89.1 <0.001
>65 years 31 54.3
sMIPI
Low 55.7 <0.001a 91.7 <0.001a
Intermediate 43.3 57.6
High 15.6 37
Ann Arbor stage
I/II 52.7 0.098 72.5 0.656
III/IV 31.3 69.3
Bone marrow involvement
Negative 50.8 0.037 75.8 0.091
Positive 15.7 57.3
ECOG PS
0 56.4 <0.001 81.1 <0.001
≥1 13.1 43.5
Ki-67 proliferation index
Low (<30%) 41.7 0.052 80 0.002
High (≥30%) 38.1 54.7
Cytology
Blastoid/pleomorphic 46.4 0.993 54.2 0.332
Classic 44 72.7
B symptoms
No 44.4 0.438 75.5 0.161
Yes 43.8 62
ASCT 0.59 (0.29–1.19)b 0.139 0.58 (0.24–1.38)b 0.215
Minimal locoregional adenopathy
No 43.2 0.595 64.2 0.478
Yes 46.1 76.2
ASCT = autologous stem cell transplantation, ECOG = Eastern Cooperative Oncology Group, MALT =
mucosa-associated lymphoid tissue, MCL = mantle cell lymphoma, MIPI = Mantle Cell Lymphoma
International Prognostic Index, PFS = progression-free survival; PS = performance status.
a trend test.
b HR (95% CI).
Figure 1. Comparison of the overall survival of 127 patients with MALT mantle
cell lymphoma and of 128 patients with classical nodal mantle cell lymphoma
(A) and comparison of the progression-free survival of 127 patients with MALT
mantle cell lymphoma and of 128 patients with nodal classic mantle cell
lymphoma (B).
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In the multivariable model for OS without Ki-67 index, MALT
presentation was a factor with a prognostic impact (HR: 0.65;
95% CI: 0.43–0.98; p=0.042) adjusted for MIPI and transplant
status.
Discussion
Twomajor clinical and biological variants ofMCL are described:
in addition to the most common classical nodal MCL, a non-nodal
variant characterized by splenomegaly and leukemic involvement
with an indolent clinical course is widely described.16
In this retrospective series, we described a peculiar presentation
of MCL characterized by ED in the absence or with minimal
nodal involvement, which we can define asMALT-oma likeMCL
due to its similarity to MALT lymphomas.
The starting hypothesis underlying the project comes from the
everyday clinical observation that patients with extranodal MCL
seemed to present a more indolent behavior compared with nodal
type. Therefore, we settled with a study within the European
Mantle Cell network centers to confirm this clinical observation.
The main objective of the study is purely descriptive of this
clinical variant; the hypothesis of a difference in terms of outcome
between the 2 groups (extranodal and nodal) has an exploratory
intention only.
The frequent involvement of gastrointestinal tract in classic
nodal MCL is well-known. In one study, 26% of patients with
MCL presented with gastrointestinal symptoms at diagnosis;
however, MCL infiltration was present histologically in the lower
gastrointestinal tract in 88% and in the upper gastrointestinal
tract in 43% of patients.9 In our series of MALT MCL, 12
patients presented with upper gastrointestinal tract involvement
while 13 had involvement of the lower tract and seven patients
showed a simultaneous involvement of upper and lower
gastrointestinal tract.
In our comparative cMCL series, the main secondary ES were
GI and Waldeyer ring while typical MALT sites, such as salivary
glands, ocular adnexa, and skin, were more frequently involved
in MALT MCL than in classical nodal cases.
We decided to include isolated Waldeyer ring cases, although
Waldeyer ring was listed as a nodal site in recent recommenda-
tions.17 However, in most studies the Waldeyer ring is historically
considered as an ES.18 Interestingly, in our cohort, there was no
difference in outcome withinMALTMCL cohort according to the
type of ES; on the other hand, the difference was still significant
between the cMCL and MCL of the Waldeyer ring.
The majority of MALT MCL cases presented with minimal
locoregional lymphadenopathy, but as for MALT marginal zone
lymphomas,19 the primary site of lymphoma involvement was
defined as the clinically dominant ES, which requires diagnostic
approach and to which primary treatment must often be directed.
On the other hand, no patients showed distant adenopathy and
during the course of disease, 82% of relapses were in ES while
only four patients relapsed with systemic nodal disease.
Noteworthy, the presence of locoregional lymphoadenopathy
did not affect the prognosis.
We also want to underline that patients in the MALT MCL
group with advanced stage (54 patients) or leukemic phase (2
patients) were included in the analysis because they showed a
predominantly extranodal disease in addition to bone marrow
involvement or leukemic disease. Majority of cases were stage IV
for multiple extranodal sites or diffuse extranodal involvement.
In addition, the clinical features at presentation seem to be
different inMALTMCL: female prevalence is higher in respect to
cMCL, LDH is less frequently elevated and limited disease at
initial staging is more common.
Patients with MALT MCL showed prolonged PFS and OS
compared with the classic nodal variant. In addition, the
extranodal variant of MCL was found to be an independent
prognostic factor for PFS, defining a better outcome. In a
multivariable model for OS, MALTMCL variant was associated
with a reduction of the risk but failed to reach significance; in the
model without Ki-67 index,MALT localization was a factor with
a prognostic impact adjusted for MIPI and transplant status.
Regarding the impact of transplant on outcome, in MALT
MCL we did not observe a statistically significant effect of
transplantation, differing from nodal MCL. However, this
should not be interpreted as a different impact of ASCT in the
2 groups since as the effect of ASCT is protective in both; the
absence of significance is probably due a smaller sample size, and
a larger series would be needed to settle this issue. Nevertheless,
MALT patients, although undergoing ASCT less frequently, still
had a better prognosis and could not benefit from a more
intensive therapy.
Strengths of our study include the systematic collection and
analysis of a large series of patients with a rare MCL clinical
variant treated in the rituximab era, the homogeneous distribu-
tion of the baseline characteristics at diagnosis (cytology, Ki-67
andMIPI), the consecutive collection during the same time period
as the controls and the comparable follow-up. Limitations
include the possible lack of some clinical prognostic data, not
standardized staging procedures between the centers and the
absence of a centralized pathological review to identify biological
markers able to recognize this clinical entity. In particular, the
impact on outcome of cytology could not be better investigated
due to the low prevalence of blastoid cytology in MALT and
nodal MCL (14 and 18 patients, respectively). In addition, we do
not have data in this setting on activity of new drugs, such as
ibrutinib20 and lenalidomide.21
Table 3
Multivariable analysis for progression-free survival and overall survival in the whole mantle cell lymphoma population (127 patients with
MALT mantle cell lymphoma and in 128 patients with nodal classic mantle cell lymphoma)
PFS OS
Parameter HR 95% CI p-value HR 95% CI p-value
MALT MCL vs nodal cMCL 0.57 0.37–0.86 0.007 0.76 0.46–1.27 0.302
sMIPI (low vs high) 0.54 0.31–0.94 0.030 0.19 0.09–0.39 <0.001
sMIPI (intermediate vs high) 0.86 0.50–1.46 0.570 0.41 0.22–0.75 0.004
ASCT (yes vs no) 0.46 0.29–0.72 0.001 0.28 0.14–0.57 <0.001
Ki-67 proliferation index (high vs low) 1.96 1.30–2.97 0.001 2.28 1.36–3.83 0.002
ASCT = autologous stem cell transplantation, HR = hazard ratio, MALT = mucosa-associated lymphoid tissue, MCL = mantle cell lymphoma, MIPI = Mantle Cell Lymphoma International Prognostic Index.
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In conclusion, this study identified a novel clinical variant
of MCL, predominantly extranodal, with a more favorable
prognosis and a more indolent course than the classical nodal
type. The possible diagnosis of this peculiar presentation of MCL
in MALT sites should be recognized, a possible overtreatment
with intensive approaches may be omitted and an initial watch
and wait strategy could be chosen in asymptomatic patients.
Additional research is needed in this form of MCL in order to
attribute its cellular origin and evaluate any molecular analogies
with classic MCL, nnMCL and with marginal zone lymphomas.
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